Impact on postmenopausal symptoms of adding continuous C-21 versus C-19 progestin to estrogen-Reference-Cited by-同舟云学术

Impact on postmenopausal symptoms of adding continuous C-21 versus C-19 progestin to estrogen

Published:1999-10 Issue:2 Volume:33 Page:153-161
ISSN:0378-5122
Container-title:Maturitas
language:en
Short-container-title:Maturitas

Author:

Wolfe Bernard M.J,Koval John J,Nisker Jeffrey A

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,General Biochemistry, Genetics and Molecular Biology

Reference19 articles.

1. A prospective 1-year study of estrogen and progestin in postmenopausal women: effects on clinical symptoms and lipoprotein lipids;Sherwin;Obstet. Gynecol.,1989

2. Use of the progestogen challenge test to reduce the risk of endometrial cancer;Gambrell;Obstet. Gynecol.,1980

3. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial, J Am Med Assoc 1995;273:199–208.

4. Incidence of endometrial hyperplasia in postmenopausal women following conjugated estrogens (Premarin) and medroxyprogesterone acetate or conjugated estrogen along. The menopause study group;Woodruff;Am. J. Obstet. Gynecol.,1994

5. Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens;Shapiro;Neng J. Med.,1985

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Medroxyprogesterone Acetate Antagonizes the Effects of Estrogen Treatment on Social and Sexual Behavior in Female Macaques;The Journal of Clinical Endocrinology & Metabolism;2004-06